All In Biotech

Drug Trial Radar · NCT06116136

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

Open Label, Non-randomized, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of S095029 (Anti-NKG2A Antibody) as a Part of Combination Therapy in Participants With Locally Advanced and Unresectable or Metastatic MSI-H/dMMR Gastro-esophageal Junction /Gastric Cancer

Last checked: Nov 19, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

48

Actual

Start

Aug 31, 2024

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Servier Bio-Innovation LLCIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC; Institut de Recherches Internationales Servier
First posted
Nov 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advanced unresectable or metastatic gastric /GEJ adenocarcinomas.

Conditions

  • MSI-H/dMMR Gastroesophageal-junction Cancer
  • MSI-H/dMMR Gastric Cancer

Interventions

  • S095029Drug

    Participants will be treated with S095029 via intravenous (IV) infusion every 3 weeks (Q3W).

  • pembrolizumab 200 mg (KEYTRUDA ®)Drug

    Participants will be treated with 200 mg of pembrolizumab via intravenous (IV) infusion every 3 weeks (Q3W).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Dose-Limiting Toxicities (DLTs)Time frame: At the end of Cycle 1 (each cycle is 21 days)
  2. Total Number of Adverse Events (AEs)Time frame: From screening to 90 days after the last dose
  3. Adverse Events (AEs) Leading to Dose Interruption, Modification, or DelaysTime frame: From screening to 90 days after the last dose
  4. Adverse Events (AEs) Leading to Dose DiscontinuationTime frame: From screening to 90 days after the last dose
  5. Objective Response Rate (ORR)Time frame: Approximately 2 years

Locations

49 sites in 15 countries. Site status is shown where the registry gives one.

  • Ocala Oncology Center Pl

    Ocala, Florida

  • Investigative Clinical Research of Indiana, Llc

    Noblesville, Indiana

  • MD Anderson Cancer Center

    Houston, Texas

  • The Queen Elizabeth Hospital

    Woodville South, Australia

  • Landeskrankenhaus (SALK)

    Salzburg, Austria

  • Med Universitat Wien-Allgemeines Krankenhaus Der Stadt Wien (AKH)

    Vienna, State of Vienna, Austria

  • Ordensklinikum Linz

    Linz, Upper Austria, Austria

  • UZ Leuven Campus Gasthuisberg

    Leuven, Belgium

  • Chu de Liege

    Liège, Belgium

  • Cepon - Centro de Pesquisas Oncologicas

    Florianópolis, Brazil

  • Supera Oncologia

    Santa Catarina, Brazil

  • Icesp - Instituto Do Câncer Do Estado de São Paulo

    São Paulo, Brazil

  • Instituto Brasileiro de Controle Do Câncer

    São Paulo, Brazil

  • Hospital Albert Einstein

    São Paulo, Brazil

  • Mount Sinai Hospital

    Toronto, Canada

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China

  • Shandong Cancer Hospital Institute

    Jinan, Shandong, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine Qingchun Branch

    Hangzhou, Zhengjiang Province, China

  • Rigshospitalet

    Copenhagen, Denmark

  • Odense Universitetshospital

    Odense, Denmark

  • Institut Bergonié

    Bordeaux, France

  • Centre Georges Francois Leclerc

    Dijon, France

  • Chru Lille - Hopital Claude Huriez

    Lille, France

  • Institut Curie

    Saint-Cloud, France

  • Inst. de Cancer de L'ouest

    Saint-Herblain, France

  • Institut de Cancerologie de Lorraine

    Vandœuvre-lès-Nancy, France

  • Semmelweis Egyetem

    Budapest, Hungary

  • Orszagos Onkologiai Intezet

    Budapest, Hungary

  • Bugat Pal Hospital

    Gyöngyös, Hungary

  • Bekes Megyei Kozponti Korhaz

    Gyula, Hungary

  • A.O.U. Seconda Università Degli Studi Di Napoli

    Campania, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumor

    Milan, Italy

  • A.O.U. Pisana-Ospedale Santa Chiara

    Pisa, Italy

  • Policlinico Universitario Agostino Gemelli

    Rome, Italy

  • Policlinico G.B. Rossi A.O.U.I. Di Verona

    Verona, Italy

  • National Cancer Center Hospital

    Chou-ku, Japan

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.